CT-38 is under clinical development by Cortene and currently in Phase I for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData, Phase I drugs for Fibromyalgia (Fibromyalgia Syndrome) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CT-38’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CT-38 overview

CT-38 is under development for the treatment of chronic fatigue syndrome (myalgic encephalomyelitis), fibromyalgia, chronic lyme disease and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through the subcutaneous route as a subcutaneous infusion.The drug candidate act by targeting corticotropin-releasing factor receptor 2 (CRF 2).

For a complete picture of CT-38’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.